Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 51, 2021 - Issue 14
184
Views
0
CrossRef citations to date
0
Altmetric
Articles

A convenient and practical synthesis of the cis isomer of the first orally active dopamine D3-Preferring D3-D2 receptor partial agonist cariprazine

, , , , , , & show all
Pages 2127-2134 | Received 29 Jan 2021, Published online: 12 May 2021
 

Abstract

A convenient and practical synthetic route was here developed for the preparation of the cis isomer of cariprazine (2), a dopamine D3-preferring D3-D2 receptor partial agonist for the treatment of schizophrenia. The key step is the concise preparation of 2-(4-(3,3-dimethylureido)cyclohexyl)acetic acid in the cis configuration via a recrystallization separation tactic. The entire synthetic procedure was performed under mild conditions avoiding any need for expensive material, hazardous conditions, ultralow temperatures or tedious purification processes. The cis configuration of 2 confirmed via X-ray crystallography.

Graphical Abstract

Additional information

Funding

This work was supported by the National Natural Science Foundation of China under Grant No. 81803371; the Shanghai Rising-Star Program under Grant No. 19QB1406200; and the National Science and Technology Major Project under Grant No. 2019ZX09301116.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.